Neos Therapeutics (NEOS) Lifted to Hold at BidaskClub

Neos Therapeutics (NASDAQ:NEOS) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other brokerages also recently issued reports on NEOS. BMO Capital Markets downgraded Neos Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 31st. Zacks Investment Research downgraded Neos Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 25th. Cantor Fitzgerald set a $20.00 price objective on Neos Therapeutics and gave the stock a “buy” rating in a research note on Monday, January 8th. Finally, Wells Fargo set a $14.00 price objective on Neos Therapeutics and gave the stock a “buy” rating in a research note on Saturday, March 17th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $15.00.

How to Become a New Pot Stock Millionaire

Shares of NEOS stock remained flat at $$8.85 during trading on Friday. The stock had a trading volume of 326,168 shares, compared to its average volume of 321,430. The stock has a market capitalization of $256.62, a PE ratio of -3.19 and a beta of -0.20. The company has a debt-to-equity ratio of 7.47, a quick ratio of 2.14 and a current ratio of 2.20. Neos Therapeutics has a twelve month low of $6.30 and a twelve month high of $13.15.

Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings data on Thursday, March 15th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.12. The firm had revenue of $7.79 million during the quarter, compared to the consensus estimate of $9.30 million. Neos Therapeutics had a negative return on equity of 437.92% and a negative net margin of 264.80%. sell-side analysts predict that Neos Therapeutics will post -1.53 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. MetLife Investment Advisors LLC purchased a new stake in shares of Neos Therapeutics during the 4th quarter worth about $134,000. Lyon Street Capital LLC raised its stake in shares of Neos Therapeutics by 247.5% during the 4th quarter. Lyon Street Capital LLC now owns 783,583 shares of the company’s stock worth $7,993,000 after purchasing an additional 558,117 shares in the last quarter. Harvest Capital Strategies LLC purchased a new stake in shares of Neos Therapeutics during the 4th quarter worth about $2,237,000. TIAA CREF Investment Management LLC raised its stake in shares of Neos Therapeutics by 53.8% during the 4th quarter. TIAA CREF Investment Management LLC now owns 90,992 shares of the company’s stock worth $928,000 after purchasing an additional 31,836 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of Neos Therapeutics by 26.6% during the 4th quarter. Teachers Advisors LLC now owns 44,408 shares of the company’s stock worth $453,000 after purchasing an additional 9,343 shares in the last quarter. 49.33% of the stock is owned by institutional investors.

WARNING: “Neos Therapeutics (NEOS) Lifted to Hold at BidaskClub” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3297415/neos-therapeutics-neos-lifted-to-hold-at-bidaskclub.html.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Analyst Recommendations for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Continental  PT Set at €260.00 by Sanford C. Bernstein
Continental PT Set at €260.00 by Sanford C. Bernstein
ABB  Given a CHF 24.50 Price Target at Morgan Stanley
ABB Given a CHF 24.50 Price Target at Morgan Stanley
The Linde Group  PT Set at €220.00 by UBS
The Linde Group PT Set at €220.00 by UBS
Marks & Spencer  Upgraded to “Neutral” by Credit Suisse Group
Marks & Spencer Upgraded to “Neutral” by Credit Suisse Group
Johnson & Johnson  Price Target Lowered to $134.00 at Citigroup
Johnson & Johnson Price Target Lowered to $134.00 at Citigroup
Denbury Resources  Director Sells $40,750.00 in Stock
Denbury Resources Director Sells $40,750.00 in Stock


© 2006-2018 Ticker Report. Google+.